vorinostat has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nesteruk, K | 1 |
| Smits, R | 1 |
| Bruno, M | 1 |
| Peppelenbosch, MP | 1 |
| Fuhler, GM | 1 |
1 other study available for vorinostat and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Upregulated β-catenin signaling does not affect survival of pancreatic cancer cells during dual inhibition of GSK3B and HDAC.
Topics: Animals; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Enzyme Inhibit | 2020 |